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Abstract 25 
Background: Monocytes significantly contribute to ischemia reperfusion injury and allograft 26 
rejection after kidney transplantation. However, the knowledge about the effects of 27 
immunosuppressive drugs on monocyte activation is limited. Conventional pharmacokinetic 28 
methods for immunosuppressive drug monitoring are not cell type-specific. In this study, 29 
phosphorylation of three signaling proteins was measured to determine the pharmacodynamic 30 
effects of immunosuppression on monocyte activation in kidney transplant patients. 31 
 32 
Methods: Blood samples from 20 kidney transplant recipients were monitored before and during 33 
the first year after transplantation. All patients received induction therapy with basiliximab, 34 
followed by tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisolone maintenance 35 
therapy. TAC whole-blood pre-dose concentrations were determined using an antibody-36 
conjugated magnetic immunoassay. Samples were stimulated with PMA/ionomycin and 37 
phosphorylation of p38MAPK, ERK, and Akt in CD14+ monocytes was quantified by phospho-38 
specific flow cytometry. 39 
 40 
 41 
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Results: Phosphorylation of p38MAPK and Akt in monocytes of immunosuppressed recipients 42 
was lower after 360 days compared with before transplantation in the unstimulated samples 43 
(mean median fluorescence intensity (MFI) reduction 36%; range -28% to 77% for p-p38MAPK 44 
and 20%; range -22% to 53% for p-Akt; p < 0.05). P-ERK was only decreased at day 4 after 45 
transplantation (mean inhibition 23%; range -52% to 73%; p < 0.05). At day 4, when the highest 46 
whole-blood pre-dose TAC concentrations were measured, p-p38MAPK and p-Akt, but not p-47 
ERK, correlated inversely with TAC (rs = -0.65; p = 0.01 and rs = -0.58; p = 0.03, respectively). 48 
Conclusions: Immunosuppressive drug combination therapy partially inhibits monocyte 49 
activation pathways after kidney transplantation. This inhibition can be determined by phospho-50 
specific flow cytometry, which enables the assessment of the pharmacodynamic effects of 51 
immunosuppressive drugs in a cell-type-specific manner. 52 
 53 
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 57 
Introduction 58 
Monocytes and macrophages contribute to the immune responses after kidney 59 
transplantation, which include tissue repair after ischemia-reperfusion injury, as well as acute 60 
cellular and antibody-mediated allograft rejection [1-5]. After ischemia-reperfusion injury, 61 
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monocytes are activated, in particular via their Toll-like receptor (TLR)-4, and infiltrate the 62 
allograft [6, 7]. Directly after transplantation and during acute cellular rejection, recipient 63 
monocytes migrate to the site of tissue injury at the graft and differentiate into CD68+ 64 
macrophages, where the presence of these macrophages is associated with graft dysfunction [4, 65 
8]. Infiltrating monocytes can differentiate locally into macrophages, which may be polarized 66 
into pro- or anti-inflammatory phenotypes. These have previously been indicated as M1 and M2 67 
macrophages, respectively, and these are now recognized as extremes in a wide functional 68 
spectrum [8-10]. Macrophages are key players in the initiation of anti-donor responses through 69 
their antigen-presenting function and production of cytokines. In addition to their role in acute 70 
cellular rejection, these cells are also involved in antibody-mediated rejection. After binding of 71 
monocyte Fc-γ receptors to donor allo-antibodies, the signal will block apoptosis and cause the 72 
accumulation of monocytes at the site of inflammation, where they produce pro-inflammatory 73 
cytokines [11-14].  74 
Activation of monocytes and macrophages is controlled, among others, by the three 75 
intracellular signaling molecules p38 Mitogen-Activated Protein Kinase (p38MAPK), 76 
Extracellular signal-Regulated Kinases 1 and 2 (ERK1/2), and AKT8 virus oncogene cellular 77 
homolog (Akt) [15-20]. Phosphorylation of these molecules by upstream kinases in the signaling 78 
pathway causes them to act on transcription factors. Phosphorylation of the MAPK members 79 
p38MAPK and ERK will lead to the activation of transcription factors (e.g., NFκB, CREB, ATF-80 
1) that regulate the transcription and translation of several genes involved in cytokine production 81 
(e.g., TNF-α, IL-1β and IL-6). In the end, activation of the MAPK pathway will affect many 82 
other monocyte functions, such as phagocytosis and differentiation into distinct macrophage 83 
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activation stages [21-23]. Similarly, Akt plays a central role in several pathways (PI3K, NFκB, 84 
and mTOR) involved in cytokine production, macrophage differentiation, and phagocytosis [24-85 
26]. 86 
After kidney transplantation, most patients are treated with combination 87 
immunosuppressive drug therapy consisting of tacrolimus (TAC), mycophenolic acid (MPA), 88 
and glucocorticoids to prevent allograft rejection [27]. The effects of these drugs on alloreactive 89 
T-cell function have been extensively characterized, but the knowledge of their effect on 90 
monocytes is limited [5]. The few in vitro studies that have been conducted in this respect have 91 
indicated that TAC and MPA affect cytokine production by monocytes [28, 29]. Furthermore, 92 
TAC did not affect phagocytosis or production of IL-1β in vitro, whereas MPA did reduce the 93 
production of IL-1β [30]. 94 
Given the important role of monocyte/macrophages in the immune responses following 95 
kidney transplantation, a deeper understanding of the effect of immunosuppressive drugs on their 96 
activation is important. Furthermore, there is an unmet need for laboratory techniques that can 97 
reliably measure such effects to guide clinical immunosuppression. The conventional method of 98 
therapeutic drug monitoring (TDM) of immunosuppressive drugs is pharmacokinetic monitoring 99 
by determining the (pre-dose) concentration of these drugs in whole blood (in case of TAC) or 100 
plasma (in case of MPA). This, however, disregards putative differences in individual 101 
responsiveness to these agents. Possibly, cell-specific and pharmacodynamic monitoring of the 102 
effects of immunosuppressive drug therapy on monocyte signaling pathway activation may be a 103 
superior strategy for TDM [31-34].  104 
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To define a new method for monitoring the impact of immunosuppression on monocyte 105 
activation we monitored and quantified the phosphorylation of p38MAPK, ERK, and Akt by 106 
phospho-specific flow cytometry, in whole-blood samples of kidney transplant patients before 107 
and after transplantation during treatment with TAC, MPA, and glucocorticoids. 108 
 109 
Materials and Methods  110 
 111 
Kidney transplant patients 112 
To determine the effect of immunosuppressive drugs on CD14+ monocyte activation, we 113 
studied 20 renal transplant patients who were followed during the first 12 months after 114 
transplantation. The present study was part of a clinical study that was approved by the Medical 115 
Ethical Committee of the Erasmus MC, University Medical Center (MEC number 2012-421, 116 
EudraCT # 2012-003169-16) [35, 36]. All participants gave written consent for collecting their 117 
blood samples. Patients were treated with 20 mg basiliximab intravenously (Simulect®, 118 
Novartis, Basel, Switzerland) on the day of transplantation and day 4 after transplantation. 119 
During the first three post-operative days, prednisolone was administered intravenously in a 120 
dosage of 100 mg/day. Subsequently, prednisolone was given orally in a dose of 20 mg and 121 
tapered to 5 mg/day by month 3. Mycophenolate mofetil (MMF; Cellcept®; Roche, Basel, 122 
Switzerland) was given in a starting dose of 2000 mg/day equally divided in two doses, and then 123 
adjusted to pre-dose concentrations (target concentration range: 1.5-3.0 µg/mL). Patients 124 
received TAC (Prograf®, Astellas Pharma Inc., Tokyo, Japan) from the day of transplantation 125 
twice a day with a starting dose of 0.2 mg/kg/day. Thereafter, TAC was adjusted to pre-dose 126 
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concentrations: 10-15 ng/mL (week 1-2), 8-12 ng/mL (week 3-4), and 5-10 ng/mL (from week 5 127 
onwards). Heparin blood samples were collected pre-transplantation and 4 days, 1 month, and 3, 128 
6, and 12 months post-transplantation.  129 
Absolute numbers of CD14+ monocytes were measured with BD multi-test 6-colour in 130 
BD TruCount Tubes (BD Biosciences, San Jose, CA). TAC whole-blood and MPA plasma pre-131 
dose concentrations were determined in EDTA blood using the antibody-conjugated magnetic 132 
immunoassay on a Dimension Xpand analyzer (Siemens HealthCare Diagnostics Inc., Newark, 133 
DE) according to the manufacturer’s instructions. The lower and upper limits of quantification of 134 
TAC were 1.5 and 30 ng/mL and for MPA 0.5 µg/mL and 15 µg/mL, respectively. For TAC, the 135 
coefficients of variation (CV) were 15.0%, 8.9%, and 11.2% for the low, middle, and high 136 
control samples, respectively. For MPA, the CV were 3.9% and 3.7%, for the low and high 137 
controls, respectively. Proficiency samples were obtained from the UK Quality Assessment 138 
Scheme (Analytical Services International Ltd, London, UK) and the laboratory successfully 139 
participates in this international proficiency testing scheme. 140 
 141 
Whole-blood phospho-specific flow cytometry 142 
Phosphorylation of p38MAPK, ERK, and Akt was measured in whole-blood samples 143 
according to the manufacturer’s instructions for phosphoprotein analysis (BD Biosciences; CV: 144 
5.6%) and as described previously [37, 38]. In short, 200 µL heparinized blood was stained for 145 
30 minutes at 37ºC with Fluorescein Isothiocyanate (FITC)-labeled mouse anti-human CD14 146 
(Serotec, Oxford, UK) and Brilliant Violet (BV) 510-labeled mouse anti-human CD3 147 
(Biolegend, San Diego, CA). After 15 minutes of staining, PMA/ionomycin (Sigma-Aldrich, 148 
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Steinheim, Germany) was added for 15 minutes to activate the blood cells. Applied final 149 
concentrations of PMA/ionomycin were 500 ng per mL/5 µg per mL for samples stained for 150 
p38MAPK and Akt, and 100 ng per mL/1 µg per mL was used for ERK, based on prior titration 151 
for optimal detection of phosphorylated protein. Thereafter, cells were fixed for 10 minutes with 152 
Lyse/Fix buffer (BD Biosciences). After permeabilization with 90% methanol at -20ºC for 30 153 
minutes, intracellular staining was performed with phycoerythrin (PE)-labeled mouse anti-p-154 
p38MAPK (clone pT180/pY182), PE-labeled mouse anti-p-Akt (clone pS473), or 155 
AlexaFluor647 (AF647)-labeled mouse anti-p-ERK1/2 (pT202/pY204) mAB (all from BD 156 
Biosciences) for 30 minutes at room temperature. Samples were analyzed on a FACS Canto II 157 
flow cytometer (BD Biosciences). Isotype controls; mouse IgG1-PE (p38MAPK and Akt, 158 
Biolegend) and mouse IgG1-AF647 (ERK; Biolegend); were included in separate tubes and 159 
served as negative controls. Interday-variability of the flow cytometer was corrected by using 160 
Cytocalbeads (Thermo Scientific, Fremont, CA) according to the manufacturer’s instructions. 161 
 162 
Statistical analysis 163 
The Median Fluorescence Intensity (MFI) was measured for the phosphorylation of 164 
p38MAPK, ERK, and Akt and data analysis was performed with Diva-version 6.0 software (BD 165 
Bioscience). MFI values were normalized using Cytocalbeads (Thermo Scientific). Statistical 166 
analysis was performed with Graph Pad Prism 5.0 (Graph Pad Software Inc., La Jolla, CA) by 167 
using paired and unpaired t-tests (after finding a p-value > 0.05 with the Kolmogorov-Smirnov 168 
test for normality for the study population). Correlations between drug concentrations and 169 
phosphorylation were calculated as the Spearman correlation coefficient. Associations between 170 
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phosphorylation levels and covariates were tested by linear regression with IBM SPSS statistics 171 
software (version 21; IBM Analytics, Chicago, Illinois, USA). Bonferroni correction was used to 172 
correct for multiple testing. A two-sided p-value < 0.05 was considered statistically significant, 173 
and for the association calculations, a two-sided p value < 0.006 was considered statistically 174 
significant after Bonferroni correction.  175 
 176 
Results 177 
Patient characteristics 178 
Baseline characteristics of the kidney transplant patients at the time of transplantation are 179 
shown in Table 1. Two patients suffered from an acute T-cell mediated rejection corresponding 180 
to an overall one-year acute rejection incidence of 10%. The rejections were classified as Banff 181 
type 1B and 2A and occurred on post-operative days 152 and 10, respectively [39, 40]. Samples 182 
from these patients were excluded for further analysis after the rejection time point. Absolute 183 
monocyte counts before and after transplantation were measured. An increase in the absolute 184 
monocyte count was measured at day 4 after transplantation (mean increase of 224 185 
monocytes/µL whole blood; p < 0.01), which can be due to the surgical procedure (Figure 1A 186 
and see Table, Supplemental Digital Content 1, which represents the absolute monocyte counts 187 
and medication overview). At months 1 and 3, the absolute counts were decreased in comparison 188 
to the baseline value (p < 0.01 and p < 0.001, respectively), while at months 6 and 12 the 189 
monocyte numbers recovered to the baseline level. As expected, the TAC pre-dose 190 
concentrations were higher at day 4 than at the later time points (p < 0.001) with a median 191 
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concentration of 15.3 ng/mL (9.1 to 28.4) at day 4 vs. 6.8 ng/mL (4.4 to 13.3) at day 360 (Figure 192 
1B and see Table, Supplemental Digital Content 1, which represents the absolute monocyte 193 
counts and medication overview). In contrast to TAC, the MPA pre-dose concentrations did not 194 
significantly change over time, which reflects TDM and the intention to keep MPA exposure 195 
constant (see Table, Supplemental Digital Content 1, which represents the absolute monocyte 196 
counts and medication overview). 197 
 198 
 199 
 200 
Phosphorylation of p38MAPK, ERK, and Akt in kidney transplant patients 201 
To assess the effects of immunosuppression on the potential of monocytes to become 202 
activated, the phosphorylation levels of p38MAPK, ERK, and Akt were measured in whole-203 
blood samples from kidney transplant patients either directly or after stimulation with 204 
PMA/ionomycin. (See Figure, Supplemental Digital Content 2A, depicting a typical gating 205 
example for the selection of CD14+ monocytes and Figure, Supplemental Digital Content 2B, 206 
showing an example of p-p38MAPK, p-ERK, and p-Akt measurements on a log scale, in which 207 
each dot represents one monocyte.)  208 
In the unstimulated samples (directly analyzed in fresh blood), the baseline 209 
phosphorylation levels of p38MAPK, ERK, and Akt were higher before transplantation than for 210 
the isotype control (p < 0.001 for all tested proteins) (Figure 2). The phosphorylation level of 211 
p38MAPK in these samples was significantly lower compared to pre-transplant levels at all test 212 
days through day 360 (p < 0.01), except at day 90 (Figure 2A). In contrast, the other MAPK 213 
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member, ERK, showed only an inhibited phosphorylation at day 4 and day 30 (p < 0.05 and p < 214 
0.001, respectively) and a constant phosphorylation pattern between day 90 and day 360 (Figure 215 
2B). The MFI values were comparable with the levels before transplantation. The third signaling 216 
protein, Akt, showed a decrease in phosphorylation levels at all-time points compared with 217 
baseline (pre-transplantation; p < 0.05) (Figure 2C). The strongest reduction was measured at 218 
day 30 (p < 0.01). 219 
To determine the effects of immunosuppression on the maximum phosphorylation 220 
capacity of each tested signaling protein, whole-blood samples were stimulated with 221 
PMA/ionomycin for 15 minutes. In these stimulated whole-blood samples, the baseline 222 
phosphorylation levels of p38MAPK, ERK, and Akt were higher before transplantation than for 223 
the isotype control (Figure 3). Again, phosphorylation of p38MAPK and Akt was decreased after 224 
transplantation compared to pre-transplant phosphorylation (Figures 3A and 3B), which was 225 
comparable with the results obtained with the directly measured samples. However, p-ERK 226 
expression showed only a decrease at day 4 (Figure 3C), which was in contrast to the significant 227 
decrease observed at both day 4 and day 30 in the unstimulated samples. 228 
One patient, who was diagnosed with acute rejection on day 152, also showed an increase 229 
in p-ERK expression over time after stimulation with PMA/ionomycin, while this was not seen 230 
for the expression of p-p38MAPK or p-Akt. (See Figure, Supplemental Digital Content 3, 231 
showing the phosphorylation measurements for a patient diagnosed with a BPAR on day 152 232 
after transplantation (red arrows)) 233 
We also calculated the percentage of phosphorylation reduction (Table II). In line with 234 
the absolute data, the decrease of p-p38MAPK was highest at day 360 (36% (SD ±31%) and 235 
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34% (SD ±28%) for the unstimulated and PMA/ionomycin stimulated samples, respectively). At 236 
the other time points tested, the decrease was 31% at most. Finally, p-Akt was reduced, with a 237 
maximum of 27%, and showed the smallest decrease at day 90 and 180. 238 
 239 
Correlations of monocyte signaling protein phosphorylation with patient treatment and 240 
demographics  241 
To determine a putative association between phosphorylation for all tested signaling proteins and 242 
the given immunosuppressive therapy, correlations between immunosuppressive drug pre-dose 243 
concentrations and MFI levels at day 4 (n = 14) and 360 (n = 19) in the unstimulated samples 244 
were calculated (Table III). Both p-p38MAPK and p-AKT, but not p-ERK, showed an inverse 245 
correlation with TAC at day 4 (rs = -0.65; p < 0.05 and rs = -0.58; p < 0.05, respectively) (see 246 
Figure, Supplemental Digital Content 4, which shows the correlation between p-p38MAPK and 247 
p-Akt and TAC pre-dose concentrations at day 4 after transplantation). At day 360, none of the 248 
tested signaling proteins was correlated with TAC pre-dose concentrations. 249 
To define whether the demographic parameters were confounding variables in this study, 250 
linear regression analysis was performed (see Table, Supplemental Digital Content 5, which 251 
shows the univariate analysis of the association between patient demographic characteristics and 252 
signaling protein phosphorylation). After correction for multiple testing, no association between 253 
the demographic characteristics of patients and the level of phosphorylation of p38MAPK, ERK, 254 
and Akt was found before transplantation or 4 and 360 days after transplantation, indicating that 255 
these parameters did not confound the results (see Table, Supplemental Digital Content 5).  256 
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 257 
Discussion 258 
Monocytes and macrophages are crucial cells in the innate immune response and are 259 
involved in the adaptive immune response via antigen presentation after kidney transplantation 260 
[3, 4]. In this pilot study, phospho-specific flow cytometry was used to monitor the effects of 261 
immunosuppressive drugs on CD14+ monocyte activation by measuring phosphorylation of three 262 
major signaling molecules: p38MAPK, ERK, and Akt.  263 
Phospho-specific flow cytometry is a relatively novel technique useful for studying the 264 
pharmacodynamic effects of immunosuppressive drug combination therapy in whole-blood 265 
samples of kidney transplant patients at the single-cell level [41-43]. In most transplant centers, 266 
TDM is performed by measuring immunosuppressive drug blood concentrations. However, this 267 
method is not cell type-specific and does not completely reflect the pharmacodynamic effects of 268 
immunosuppressants on monocytes and other immune cells [44]. Furthermore, classic, 269 
pharmacokinetic TDM of TAC in general is based on pre-dose concentrations that have an 270 
imperfect correlation with the area under the concentration vs. time curve and do not accurately 271 
predict acute rejection [45, 46].  272 
In recent years, several methods for pharmacodynamic TDM have been investigated, 273 
including the measurement of calcineurin phosphatase activity, cytokine production, and the 274 
expression of NFAT-regulated genes [47-50]. However, until now these methods have not found 275 
their way into routine clinical practice, because of poor correlation with clinical outcomes, 276 
controversial data on the correlation with pharmacokinetic parameters, and high interindividual 277 
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variability, respectively [44]. Furthermore, these pharmacodynamic assays were developed to 278 
study the effect on T-cells and it is unknown whether these methods can also be used for 279 
studying the effect of immunosuppressants on monocytes.  280 
A correlation between reduction of p-p38MAPK levels in T-cells and TAC blood 281 
concentrations after kidney transplantation was previously found with phospho-specific flow 282 
cytometry [37, 51]. In the present study, CD14+ monocytes from kidney transplant patients 283 
showed a decrease in p-p38MAPK and p-Akt with a maximum of 36% and 20%, respectively, as 284 
compared to pre-transplant levels. These results are in line with previous in vitro findings: 285 
healthy control blood samples spiked with TAC showed a maximum p-p38MAPK and p-Akt 286 
inhibition in monocytes of 33% and 14%, respectively [30]. In the in vitro study, spiking with 287 
TAC did not affect the production of IL-1β or the phagocytosis by monocytes. Only a slight 288 
change in monocyte differentiation toward an M2-like phenotype was measured in the presence 289 
of high TAC concentrations [30]. In contrast to the reduction of p-p38MAPK and p-Akt, 290 
phosphorylation of the other MAPK member, ERK, was only significantly reduced within the 291 
first month after transplantation. The maximum decrease at day 4 and day 30 was 39%, 292 
indicating a stronger reduction of p-ERK than for p-p38MAPK and p-Akt. Of note, the 293 
expression of p-ERK after stimulation increased with time after transplantation in the one patient 294 
suffering from an acute rejection, indicating a potential role for this signaling molecule in acute 295 
rejection.  296 
The decreased phosphorylation found for the signaling molecules indicates that the innate 297 
immune response of monocytes is not completely inhibited after kidney transplantation. The 298 
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incomplete inhibition causes a residual monocyte activity that may contribute to immune 299 
responses after kidney transplantation, such as chronic antibody-mediated rejection. The residual 300 
monocyte activity is reflected in the retained ability of monocytes to produce pro- and anti-301 
inflammatory cytokines after transplantation [52]. Moreover, the PI3K/Akt pathway is the main 302 
regulator of cell survival in human monocytes and decreased activation of this pathway is 303 
associated with immunological quiescence after kidney transplantation [53, 54]. It has also been 304 
suggested that p-Akt inhibition causes impairment in IL-10 production and upregulation of p-305 
p38MAPK and p-ERK1/2 after transplantation [16, 55]. Furthermore, MAPK pathways are 306 
involved in monocyte adhesion (ERK) and chemotaxis (p38MAPK) [56, 57]. p-ERK controls the 307 
differentiation, survival, and homeostasis of monocytes when the cells are stimulated with a 308 
growth or survival factor, such as M-CSF (macrophage colony-stimulating factor), while 309 
inhibition of p-ERK causes cell apoptosis [58, 59]. Altogether, this shows that monitoring of 310 
signaling pathway activation is important to control monocyte-mediated immune responses after 311 
transplantation. 312 
Multiple factors can influence signaling protein phosphorylation, including 313 
immunosuppressive drugs. TAC showed a significant negative correlation with phosphorylation 314 
intensity of p38MAPK and Akt, suggesting that the inhibition of p-p38MAPK and p-Akt is TAC 315 
concentration dependent. However, these correlations were only observed at day 4, when TAC 316 
pre-dose concentrations were highest, and are in line with the findings of the previous in vitro 317 
study [30]. No other associations were observed between patient demographics and signaling 318 
protein phosphorylation, indicating that phospho-specific flow cytometry is a promising tool to 319 
detect TAC effects after transplantation.  320 
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These data also indicate that TAC has the most important role in the inhibition of 321 
intracellular signaling pathways in monocytes within 4 days after transplantation, while the 322 
inhibition at later time points may be due to the presence of prednisolone in the blood samples. 323 
In mouse peritoneal macrophages, the glucocorticoid receptor is involved in the inhibition of p-324 
p38MAPK, while p-ERK and p-Akt are not affected by glucocorticoid signaling [60]. This 325 
suggests that the given prednisolone doses in the present study could only inhibit p-p38MAPK. 326 
However, the prednisolone blood concentrations were not measured in this study, and more 327 
research is needed to distinguish between the individual effects of glucocorticoids on monocyte 328 
intracellular activation pathways. 329 
The present study provides preliminary data on the use of phospho-specific flow 330 
cytometry for clinical diagnostics. More research is needed to translate the present findings on 331 
phosphorylation status into meaningful clinical diagnostics. For example, all tested proteins in 332 
the present study showed the least percentage of phosphorylation inhibition between day 90 and 333 
180 after transplantation, but it is unknown whether this will also increase the risk of monocyte-334 
mediated rejection. The technique is ready to be used for clinical diagnostics of malignancies in 335 
the field of hematology and oncology [61, 62]. However, for daily clinical TDM of 336 
immunosuppressive drugs, this technique needs more validation to become a standardized 337 
procedure. The labor intensity, reproducibility, and cost-effectiveness of the technique should be 338 
established. However, compared to western blotting, phospho-specific flow cytometry is cell 339 
specific and a relatively rapid method to measure cell signaling pathway activation. For example, 340 
the turnaround time of the test used in the present study is only 4 hours. The next step would be 341 
to study the correlation of phosphorylation profiles with pharmacokinetic parameters and to find 342 
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a threshold of phosphorylation that indicates a risk for rejection. In a future prospective study, 343 
blood samples from kidney transplant patients who might develop rejection should be measured 344 
and the predictive value of the phosphorylation status of the different molecules in monocytes, p-345 
p38MAPK, p-ERK, and p-Akt, should be assessed. It could also be informative to combine 346 
phospho-specific flow cytometry with the measurement of intra-lymphocytic or tissue TAC 347 
concentrations. The latter directly quantifies the TAC concentration in its target compartment 348 
and therefore possibly relates more closely to efficacy and toxicity. Studies in intracellular TAC 349 
concentrations have hitherto been performed in lymphocytes and peripheral blood mononuclear 350 
cells, as well as in kidney and liver tissue, but not in purified monocytes [63-67]. It may also be 351 
of interest to combine phospho-specific flow cytometry with novel biomarkers such as graft-352 
derived cell-free DNA. Graft-derived cell-free DNA may serve as a “liquid biopsy” in 353 
transplantation, although this biomarker requires further validation and it remains to be 354 
determined whether it may aid in improving TDM of TAC and other immunosuppressive drugs 355 
[68, 69]. 356 
 357 
Conclusion 358 
Phospho-specific flow cytometry is a technique to measure the pharmacodynamic effects of 359 
immunosuppressive drug therapy on CD14+ monocytes. The use of this technique demonstrated 360 
that monocyte activation pathways are only partially inhibited by TAC, MMF, and prednisolone 361 
combination therapy after kidney transplantation. 362 
 363 
 364 
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 542 
Figure Legends 543 
Figure 1. Absolute monocyte numbers and TAC pre-dose concentrations before and after 544 
transplantation. A) Absolute monocyte count in patients before and after transplantation 545 
measured as the number of CD14+ monocytes/µL whole blood. B) TAC blood pre-dose 546 
concentrations within the first year after transplantation. Data are plotted as box and whiskers 547 
indicating total range. Target ranges for both drugs are indicated in light grey in the background. 548 
(n = 20) *) p < 0.05, **) p < 0.01, ***) p < 0.001 549 
 550 
 551 
Figure 2. Unstimulated phosphorylation of intracellular signaling molecules before and after 552 
transplantation in CD14+ monocytes. Unstimulated phosphorylation of p38MAPK (A), ERK (B), 553 
and Akt (C) in kidney transplant patients before and within 1 year after transplantation compared 554 
to isotype controls. Within 1 month after transplantation, phosphorylation of p38MAPK, ERK, 555 
and Akt was decreased. After 1 month, only p-p38MAPK and p-Akt showed a decrease 556 
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compared to the samples before transplantation. (n = 20 patients) *) p < 0.05, **) p < 0.01, ***) 557 
p < 0.001 558 
 559 
Figure 3. PMA/ionomycin-stimulated phosphorylation of signaling molecules in CD14+ 560 
monocytes before and within 1 year after transplantation. Blood samples were stimulated with 561 
PMA/ionomycin to determine the maximum phosphorylation capacity for each signaling protein 562 
in monocytes. Phosphorylation of p38MAPK (A), ERK (B), and Akt (C) was higher compared 563 
to the isotype controls. During 1 year after transplantation, p-p38MAPK and p-Akt, but not p-564 
ERK, were decreased, which is in comparison with the unstimulated results. (n = 20 patients) *) 565 
p < 0.05, **) p < 0.01, ***) p < 0.001 566 
 567 
Table I: Patient demographics and baseline characteristics  568 
 569 
 
Study population 
(n = 20) 
Age in years  55 (21-76) 
Male/female 16 (80%)/4 (20%) 
Ethnicity  
• Caucasian 16 (80%) 
• African 2 (10%) 
• Asian 2 (10%) 
Body weight (kg, mean and range) 88.5 (51.4-120.0) 
HLA A mismatch 1.4 (± 0.5) 
HLA B mismatch  1.5 (± 0.5) 
HLA DR mismatch 1.3 (± 0.4) 
Current PRA (%) (mean and range) 2.5 (0-17) 
Peak PRA (%) (mean and range) 4.2 (0-21) 
Donor age in years  51 (22-80) 
Living-related/living-unrelated donor  5 (25%)/15 (75%) 
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Cause of end-stage renal disease   
• Diabetes mellitus 7 (35%) 
• Hypertension 5 (25%) 
• IgA nephropathy 3 (15%) 
• Polycystic kidney disease 3 (15%) 
• Obstructive nephropathy 1 (5%) 
• Unknown 0 (0%) 
• Other 1 (5%) 
Renal replacement therapy prior to 
transplantation  
• None (pre-emptive) 12 (60%) 
• Hemodialysis 6 (30%) 
• Peritoneal dialysis 2 (10%) 
Time on dialysis (days) (mean and 
range) 783 (465-1519) 
 570 
Continuous variables are presented as means (± SD) or medians (range) and categorical variables 571 
as numbers (plus percentages), unless otherwise specified. 572 
All patients received their first kidney transplant. 573 
HLA, human leukocyte antigen; PRA, panel reactive antibodies (current = PRA at time of 574 
transplantation, peak = historically highest measured PRA); SD, standard deviation. 575 
 576 
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Table II: Reduction of signaling molecule phosphorylation  577 
% inhibition 
(mean ± SD) 
p38MAPK ERK Akt 
 Unstim PMA/iono Unstim PMA/iono Unstim PMA/iono 
Day 4 30% (±26%) ** 24% (±14%) ** 23% (±34%) * 18% (±25%) * 16% (±20%) * 27% (±18%) *** 
Day 30 24% (±24%) ** 16% (±24%) ** 39% (±22%) *** 12% (±37%) 20% (±17%) ** 21% (±22%) * 
Day 90 13% (±49%) 17% (±31%)  19% (±51%) 7% (±31%) 17% (±21%) * 21% (±18%) ** 
Day 180 31% (±16%) ** 27% (±27%) ** 16% (±49%) -5% (±38%) 13% (±26%) * 25% (±27%) ** 
Day 360 36% (±31%) ** 34% (±28%) ** 16% (±61%) -28% (±60%) 20% (±23%) * 27% (±25%) ** 
 578 
Unstim) unstimulated samples; PMA/iono) PMA/ionomycin stimulated samples 579 
Significant difference with baseline phosphorylation: *) p < 0.05; **) p < 0.01; ***) p < 0.001 580 
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Table III: Correlation between signaling molecule phosphorylation (unstimulated) and 581 
immunosuppressive drug trough blood concentrations at day 4 and day 360 after transplantation 582 
Correlation  p-p38MAPK p-ERK p-Akt 
  rs p value rs p value rs p value  
day 4 Tacrolimus -0.65 0.012 -0.15 0.615 -0.58 0.030 
day 360 Tacrolimus -0.21 0.512 0.20 0.563 -0.10 0.780 
  583 
rs = Spearman’s Rank Correlation Coefficient 584 
 585 
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